


Ledipasvir D-tartrate

Chemical Properties

CAS No. :	1502654-87-6
Formula:	C53H60F2N8O12
Molecular Weight:	1039.09
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Ledipasvir D-tartrate (GS-5885 D-tartrate) is an HCV NS5A inhibitor that suppresses viral overphosphorylation and replication, and is used for the treatment of hepatitis C virus.
Targets(IC50)	HCV Protease
In vitro	<p>Method: Ledipasvir D-tartrate antiviral activity against HCV genotypes 1a and 1b and protein-adjusted EC50 values were determined using replicon systems. Protein binding and inhibitory effects on the JFH/3a-NS5A replicon were also evaluated.</p> <p>Result: Ledipasvir D-tartrate exhibited EC50 values of 31 pM and 4 pM against genotypes 1a and 1b, respectively, with protein-adjusted EC50 values of 210 pM and 27 pM. It showed high protein binding. The EC50 against the JFH/3a-NS5A replicon was 141 nM. [2]</p>
In vivo	<p>Method: Pharmacokinetic parameters of Ledipasvir D-tartrate, including plasma half-life, systemic clearance (CL), and steady-state volume of distribution (Vss), were measured in rats and dogs to evaluate its in vivo pharmacokinetic properties.</p> <p>Result: Ledipasvir D-tartrate exhibited favorable plasma half-lives in rats (1.83 ± 0.22 hours) and dogs (2.63 ± 0.18 hours), low systemic clearance, and moderate Vss values greater than total body water volume. The drug demonstrated good bioavailability and long half-lives in various primates, with predicted low clearance in humans. [1]</p>

Solubility Information

Solubility	DMSO: 20 mg/mL (19.25 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.92 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one.</i>

A DRUG SCREENING EXPERT

In vivo Formulation	<i>Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>
---------------------	--

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.9624 mL	4.8119 mL	9.6238 mL
5 mM	0.1925 mL	0.9624 mL	1.9248 mL
10 mM	0.0962 mL	0.4812 mL	0.9624 mL
50 mM	0.0192 mL	0.0962 mL	0.1925 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Link JO, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. *J Med Chem.* 2014 Mar 13;57(5):2033-46.

Hernandez D, et al. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. *J Clin Virol.* 2013 May;57(1):13-8.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481